Close

Dimension Therapeutics (DMTX) FDA Accepts IND for DTX301 to Treat OTC Deficiency

December 13, 2016 8:01 AM EST Send to a Friend
Dimension Therapeutics, Inc. (NASDAQ: DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login